Skip to content
How we help
Investors
Best-in-class, real-time data and expert analyses designed to give you an edge in alpha generation.
Learn More
Companies
Real-time customer behavior, performance benchmarking, and market insights from investment-grade data and expert analysts.
Learn More
Consultants
Get visibility into thousands of consumer and healthcare companies across hundreds of sectors.
Learn More
Our Data
Insights
About Us
Our Company
Press
Careers
Login
Start for free
Earnest Insights
Earnest Healthcare
GLP-1 Series Part 4: End of Mounjaro’s bridge program drove improved gross-to-net
GLP-1 Series Part 3: Mounjaro driving largest declines in insulin usage
GLP-1 Series Part 2: Mounjaro persistence beats Ozempic in type II diabetes
GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in...
Camzyos: early claims data trends pointing to strong therapy adherence
Discontinuations damper Relyvrio’s launch
Orladeyo: A Tough Pill to Swallow for Competitors in the HAE Space
Wegovy is Back on Shelves, Picking up Ozempic’s Momentum in Obesity
Tepezza Disrupted
Narcolepsy Treatment: Xywav Making Waves
Tepezza Disrupted
How we help
Investors
Companies
Consultants
Our Data
Insights
About Us
Our Company
Press
Careers
Login
Start for free
arrow-down
caret-down-menu
caret-down
check
close
facebook-square
filter
hamburger
instagram-square
linkedin-square
mobile-parent-indicator
pause
play
twitter-square